Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2019-05-16 Regulatory Filings
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 13, 2019. It announces the issuance of a press release regarding Phase 2b clinical trial results. The document is short (3064 characters) and primarily serves as an announcement of an event and a press release attachment, not a full financial report or detailed filing. It does not contain financial statements or detailed analysis but rather a notification of an event and reference to an exhibit (press release). Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-05-16 English
10-Q
Interim / Quarterly Report Q1 2019
2019-05-06 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the Annual Meeting of Minerva Neurosciences, Inc. It includes voting items such as election of directors and ratification of the independent auditor. The document is a solicitation of shareholder votes and provides information about the proxy materials and meeting logistics. It is not the proxy statement itself but additional materials related to the proxy solicitation. According to the filing definitions, materials sent to shareholders to provide information and request votes for meetings are classified as Proxy Solicitation & Information Statement (PSI). The document length (5462 characters) and content confirm it is not a full annual report or other financial report but proxy solicitation materials.
2019-04-17 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-17 English
RW
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the SEC regarding the withdrawal of a Post-Effective Amendment to a Registration Statement on Form S-3. It references regulatory rules under the Securities Act and requests the withdrawal of the registration statement and crediting of fees. There is no financial data, report content, or presentation of company performance. The document is a regulatory communication about a filing withdrawal, not a financial report or announcement of results. It fits the category of a Regulatory Filing (RNS) as it is a compliance-related submission to the SEC that does not fit other specific categories.
2019-04-11 English
10-K
Annual Report FY 2018
2019-03-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.